nCRT Combined With Tislelizumab Versus nCRT for Local Advanced Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1
antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus
neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally
advanced resectable esophageal squamous cell carcinoma (cT1b-3N1-2M0, cT3-4aN0M0) patient.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborators:
Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences First Affiliated Hospital of Wenzhou Medical University Ningbo Medical Center Lihuili Hospital Shanghai Chest Hospital Shanghai Minhang Central Hospital Shanghai Qingpu Central Hospital The First People's Hospital of Changzhou Tianjin Medical University Cancer Institute and Hospital Xuhui Central Hospital, Shanghai Zhejiang Cancer Hospital Zhongshan Hospital, Fudan University (Xiamen Branch)